JP2011500694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500694A5 JP2011500694A5 JP2010530050A JP2010530050A JP2011500694A5 JP 2011500694 A5 JP2011500694 A5 JP 2011500694A5 JP 2010530050 A JP2010530050 A JP 2010530050A JP 2010530050 A JP2010530050 A JP 2010530050A JP 2011500694 A5 JP2011500694 A5 JP 2011500694A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolidin
- phenyl
- ylmethyl
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 naphthidylyl Chemical group 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- BAYMNWJMIJZNLH-UHFFFAOYSA-N 2-[2-(2-methoxyethyl)hydrazinyl]ethanol Chemical compound COCCNNCCO BAYMNWJMIJZNLH-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- RFGPIJJAGNRBBJ-UHFFFAOYSA-N 2,5-dioxo-3,4-dihydro-1h-1,4-benzodiazepine-8-carboxylic acid Chemical compound N1C(=O)CNC(=O)C=2C1=CC(C(=O)O)=CC=2 RFGPIJJAGNRBBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- YGVKRUNDMHLLCQ-UHFFFAOYSA-N 2-methyl-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-3h-benzimidazole-5-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=C4N=C(C)NC4=CC=3)=CC=2)CC1 YGVKRUNDMHLLCQ-UHFFFAOYSA-N 0.000 claims 1
- ZZKTVVTWOFEGLU-UHFFFAOYSA-N 3,4-dihydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(O)C(O)C(C)(C)OC2=C1 ZZKTVVTWOFEGLU-UHFFFAOYSA-N 0.000 claims 1
- PVURUGSJWMVILG-QFBILLFUSA-N 3,5-dimethyl-n-[2-methyl-4-[(3r)-3-[[(2s)-2-methylpyrrolidin-1-yl]methyl]pyrrolidin-1-yl]phenyl]-1,2-oxazole-4-carboxamide Chemical compound C[C@H]1CCCN1C[C@@H]1CN(C=2C=C(C)C(NC(=O)C3=C(ON=C3C)C)=CC=2)CC1 PVURUGSJWMVILG-QFBILLFUSA-N 0.000 claims 1
- SBDKIMDTYGYSRR-RBUKOAKNSA-N 3-fluoro-n-[2-methyl-4-[(3r)-3-[[(2s)-2-methylpyrrolidin-1-yl]methyl]pyrrolidin-1-yl]phenyl]benzamide Chemical compound C[C@H]1CCCN1C[C@@H]1CN(C=2C=C(C)C(NC(=O)C=3C=C(F)C=CC=3)=CC=2)CC1 SBDKIMDTYGYSRR-RBUKOAKNSA-N 0.000 claims 1
- MIDVGCQBOUDVOU-UHFFFAOYSA-N 4-(1-acetylpiperidin-3-yl)-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]benzamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=CC(=CC=3)C3CN(CCC3)C(C)=O)=CC=2)CC1 MIDVGCQBOUDVOU-UHFFFAOYSA-N 0.000 claims 1
- DKQIZBBOUKKSND-UHFFFAOYSA-N 4-(hydroxymethyl)-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]benzamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=CC(CO)=CC=3)=CC=2)CC1 DKQIZBBOUKKSND-UHFFFAOYSA-N 0.000 claims 1
- JUTVIVDYDLACSP-UHFFFAOYSA-N 4-imidazol-1-yl-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]benzamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=CC(=CC=3)N3C=NC=C3)=CC=2)CC1 JUTVIVDYDLACSP-UHFFFAOYSA-N 0.000 claims 1
- GTJIDFLZYALYBZ-VQTJNVASSA-N 5-fluoro-2-methyl-n-[2-methyl-4-[(3r)-3-[[(2s)-2-methylpyrrolidin-1-yl]methyl]pyrrolidin-1-yl]phenyl]benzamide Chemical compound C[C@H]1CCCN1C[C@@H]1CN(C=2C=C(C)C(NC(=O)C=3C(=CC=C(F)C=3)C)=CC=2)CC1 GTJIDFLZYALYBZ-VQTJNVASSA-N 0.000 claims 1
- WNAJVCZJSUGNGK-UHFFFAOYSA-N 5-methoxy-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-1h-indole-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2NC=1C(=O)NC(C(=C1)C)=CC=C1N(C1)CCC1CN1CCCC1C WNAJVCZJSUGNGK-UHFFFAOYSA-N 0.000 claims 1
- HPWRTALUZAGHAC-UHFFFAOYSA-N 6-methoxy-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-1-benzofuran-2-carboxamide Chemical compound O1C2=CC(OC)=CC=C2C=C1C(=O)NC(C(=C1)C)=CC=C1N(C1)CCC1CN1CCCC1C HPWRTALUZAGHAC-UHFFFAOYSA-N 0.000 claims 1
- MQDCWGAMNFCVGK-UHFFFAOYSA-N 6-methyl-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-4-oxochromene-2-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3OC4=CC=C(C)C=C4C(=O)C=3)=CC=2)CC1 MQDCWGAMNFCVGK-UHFFFAOYSA-N 0.000 claims 1
- CBNPGIGVQJTMTP-UHFFFAOYSA-N 7-chloro-n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-4-oxo-1h-quinoline-3-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C(=C4C=CC(Cl)=CC4=NC=3)O)=CC=2)CC1 CBNPGIGVQJTMTP-UHFFFAOYSA-N 0.000 claims 1
- WHJTTWIMQIGVJK-UHFFFAOYSA-N 7-methyl-4-oxo-1h-1,8-naphthyridine-3-carboxylic acid Chemical compound N1C=C(C(O)=O)C(=O)C=2C1=NC(C)=CC=2 WHJTTWIMQIGVJK-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- FUCHFZJCZBCGQN-UHFFFAOYSA-N CC1CCCN1CC2CCN(C2)C3=C(C(=C(C(=C3)C)N4CC=CC(=C4)C5CCCN5C)NCCO)Cl Chemical compound CC1CCCN1CC2CCN(C2)C3=C(C(=C(C(=C3)C)N4CC=CC(=C4)C5CCCN5C)NCCO)Cl FUCHFZJCZBCGQN-UHFFFAOYSA-N 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- LDVHVKUQVITEHD-VQTJNVASSA-N n-[2-methyl-4-[(3r)-3-[[(2s)-2-methylpyrrolidin-1-yl]methyl]pyrrolidin-1-yl]phenyl]cyclohexanecarboxamide Chemical compound C[C@H]1CCCN1C[C@@H]1CN(C=2C=C(C)C(NC(=O)C3CCCCC3)=CC=2)CC1 LDVHVKUQVITEHD-VQTJNVASSA-N 0.000 claims 1
- PGMSQXCSQIDOIK-ZWKOTPCHSA-N n-[2-methyl-4-[(3r)-3-[[(2s)-2-methylpyrrolidin-1-yl]methyl]pyrrolidin-1-yl]phenyl]furan-3-carboxamide Chemical compound C[C@H]1CCCN1C[C@@H]1CN(C=2C=C(C)C(NC(=O)C3=COC=C3)=CC=2)CC1 PGMSQXCSQIDOIK-ZWKOTPCHSA-N 0.000 claims 1
- YVUVBYIJLGSONB-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-1,3-benzodioxole-5-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=C4OCOC4=CC=3)=CC=2)CC1 YVUVBYIJLGSONB-UHFFFAOYSA-N 0.000 claims 1
- MOLASSDTWOISGN-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-1h-indole-6-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=C4NC=CC4=CC=3)=CC=2)CC1 MOLASSDTWOISGN-UHFFFAOYSA-N 0.000 claims 1
- QGSSYCAXPLSKOO-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-2,3-dihydro-1-benzofuran-5-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=C4CCOC4=CC=3)=CC=2)CC1 QGSSYCAXPLSKOO-UHFFFAOYSA-N 0.000 claims 1
- FKNQXFIMZSMBLL-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-4-(3-methyl-5-oxo-4h-pyrazol-1-yl)benzamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=CC(=CC=3)N3C(CC(C)=N3)=O)=CC=2)CC1 FKNQXFIMZSMBLL-UHFFFAOYSA-N 0.000 claims 1
- JFCIRXKCYXZKKC-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-6-(phenylmethoxymethyl)pyridine-3-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=NC(COCC=4C=CC=CC=4)=CC=3)=CC=2)CC1 JFCIRXKCYXZKKC-UHFFFAOYSA-N 0.000 claims 1
- FKPVLOBWGQUIAM-UHFFFAOYSA-N n-[2-methyl-4-[3-[(2-methylpyrrolidin-1-yl)methyl]pyrrolidin-1-yl]phenyl]-6-pyrrol-1-ylpyridine-3-carboxamide Chemical compound CC1CCCN1CC1CN(C=2C=C(C)C(NC(=O)C=3C=NC(=CC=3)N3C=CC=C3)=CC=2)CC1 FKPVLOBWGQUIAM-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98060207P | 2007-10-17 | 2007-10-17 | |
| US60/980,602 | 2007-10-17 | ||
| PCT/US2008/079758 WO2009052063A1 (en) | 2007-10-17 | 2008-10-14 | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500694A JP2011500694A (ja) | 2011-01-06 |
| JP2011500694A5 true JP2011500694A5 (enExample) | 2011-11-24 |
| JP5377504B2 JP5377504B2 (ja) | 2013-12-25 |
Family
ID=40137955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530050A Expired - Fee Related JP5377504B2 (ja) | 2007-10-17 | 2008-10-14 | 置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8227504B2 (enExample) |
| EP (1) | EP2205558B1 (enExample) |
| JP (1) | JP5377504B2 (enExample) |
| KR (1) | KR20100092443A (enExample) |
| CN (1) | CN101903342B (enExample) |
| AU (1) | AU2008312636B2 (enExample) |
| BR (1) | BRPI0818766A2 (enExample) |
| CA (1) | CA2702834C (enExample) |
| DK (1) | DK2205558T3 (enExample) |
| ES (1) | ES2392122T3 (enExample) |
| IL (1) | IL205000A0 (enExample) |
| MA (1) | MA31857B1 (enExample) |
| MX (1) | MX2010004003A (enExample) |
| MY (1) | MY150210A (enExample) |
| NZ (1) | NZ584691A (enExample) |
| PT (1) | PT2205558E (enExample) |
| RU (1) | RU2477721C2 (enExample) |
| WO (1) | WO2009052063A1 (enExample) |
| ZA (1) | ZA201002113B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101903341B (zh) | 2007-10-17 | 2012-10-03 | 赛诺菲-安万特 | 取代的n-苯基-联吡咯烷脲及其治疗用途 |
| AU2008312638B2 (en) * | 2007-10-17 | 2013-05-16 | Sanofi-Aventis | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| MY151348A (en) | 2007-10-17 | 2014-05-15 | Sanofi Aventis | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| AR074467A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| EP2569303A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| JP5784110B2 (ja) | 2010-05-11 | 2015-09-24 | サノフイ | 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用 |
| AR081383A1 (es) | 2010-05-11 | 2012-08-29 | Sanofi Aventis | N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central. |
| TW201206939A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| TW201202251A (en) | 2010-05-11 | 2012-01-16 | Sanofi Aventis | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| JP2013529198A (ja) * | 2010-05-11 | 2013-07-18 | サノフイ | 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用 |
| RU2562461C1 (ru) * | 2014-04-30 | 2015-09-10 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Спин-меченое производное кинуренина и способ его получения |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| EP1556046A1 (en) * | 2002-10-23 | 2005-07-27 | Janssen Pharmaceutica N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| ES2335305T3 (es) * | 2005-03-17 | 2010-03-24 | Eli Lilly And Company | Derivados de pirrolidina como antagonistas del receptor h3 de histamina. |
| WO2006107661A1 (en) * | 2005-04-01 | 2006-10-12 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| MX2007016216A (es) * | 2005-07-01 | 2008-03-11 | Lilly Co Eli | Agenes del receptor de histamina h3, preparacion y usos terapeuticos. |
| AU2006308167A1 (en) * | 2005-10-27 | 2007-05-03 | Ucb Pharma, S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| AU2007214709A1 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
| CN101903341B (zh) | 2007-10-17 | 2012-10-03 | 赛诺菲-安万特 | 取代的n-苯基-联吡咯烷脲及其治疗用途 |
| AU2008312638B2 (en) * | 2007-10-17 | 2013-05-16 | Sanofi-Aventis | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| MY151348A (en) | 2007-10-17 | 2014-05-15 | Sanofi Aventis | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
-
2008
- 2008-10-14 CA CA2702834A patent/CA2702834C/en not_active Expired - Fee Related
- 2008-10-14 PT PT08839706T patent/PT2205558E/pt unknown
- 2008-10-14 BR BRPI0818766 patent/BRPI0818766A2/pt not_active IP Right Cessation
- 2008-10-14 EP EP08839706A patent/EP2205558B1/en active Active
- 2008-10-14 RU RU2010119530/04A patent/RU2477721C2/ru not_active IP Right Cessation
- 2008-10-14 NZ NZ584691A patent/NZ584691A/en not_active IP Right Cessation
- 2008-10-14 AU AU2008312636A patent/AU2008312636B2/en not_active Ceased
- 2008-10-14 JP JP2010530050A patent/JP5377504B2/ja not_active Expired - Fee Related
- 2008-10-14 MY MYPI2010001275A patent/MY150210A/en unknown
- 2008-10-14 ES ES08839706T patent/ES2392122T3/es active Active
- 2008-10-14 WO PCT/US2008/079758 patent/WO2009052063A1/en not_active Ceased
- 2008-10-14 CN CN2008801212575A patent/CN101903342B/zh not_active Expired - Fee Related
- 2008-10-14 KR KR1020107010710A patent/KR20100092443A/ko not_active Ceased
- 2008-10-14 MX MX2010004003A patent/MX2010004003A/es active IP Right Grant
- 2008-10-14 DK DK08839706.2T patent/DK2205558T3/da active
-
2010
- 2010-03-15 US US12/724,044 patent/US8227504B2/en not_active Expired - Fee Related
- 2010-03-25 ZA ZA2010/02113A patent/ZA201002113B/en unknown
- 2010-04-11 IL IL205000A patent/IL205000A0/en unknown
- 2010-05-17 MA MA32849A patent/MA31857B1/fr unknown